{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:22Z","timestamp":1788355342753,"version":"build-2803163510"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,15]]},"DOI":"10.1097\/tp.0b013e3181b724a5","type":"journal-article","created":{"date-parts":[[2009,10,2]],"date-time":"2009-10-02T03:15:01Z","timestamp":1254453301000},"page":"904-910","source":"Crossref","is-referenced-by-count":21,"title":["Alemtuzumab Versus Interleukin-2 Receptor Antibodies Induction in Living Donor Kidney Transplantation"],"prefix":"10.1097","volume":"88","author":[{"given":"Marcelo S.","family":"Sampaio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kadiyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagbir","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphamai","family":"Bunnapradist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210211","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/01.tp.0000296680.75175.67","article-title":"Alemtuzumab.","volume":"84","author":"Weaver","year":"2007","journal-title":"Transplantation"},{"key":"R2-10-20210211","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): A systematic review in organ transplantation.","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"key":"R3-10-20210211","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.TP.0000128625.29654.EB","article-title":"The use of Campath-1H as induction therapy in renal transplantation: Preliminary results.","volume":"78","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"R4-10-20210211","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transplant"},{"key":"R5-10-20210211","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial.","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"R6-10-20210211","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2008.02260.x","article-title":"Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells.","volume":"8","author":"Pascual","year":"2008","journal-title":"Am J Transplant"},{"key":"R7-10-20210211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation.","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"R8-10-20210211","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/TP.0b013e31816f60cf","article-title":"Campath induction for kidney transplantation: Report of 297 cases.","volume":"85","author":"Ortiz","year":"2008","journal-title":"Transplantation"},{"key":"R9-10-20210211","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.transproceed.2008.02.026","article-title":"Experience with alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.","volume":"40","author":"Baez","year":"2008","journal-title":"Transplant Proc"},{"key":"R10-10-20210211","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1111\/j.1600-6143.2006.01495.x","article-title":"Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.","volume":"6","author":"Tan","year":"2006","journal-title":"Am J Transplant"},{"key":"R11-10-20210211","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction\u2014Long-term results.","volume":"5","author":"Kaufman","year":"2005","journal-title":"Am J Transplant"},{"key":"R12-10-20210211","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.tp.0000281942.97406.89","article-title":"Alemtuzumab induction in deceased donor kidney transplantation.","volume":"84","author":"Huang","year":"2007","journal-title":"Transplantation"},{"key":"R13-10-20210211","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/TP.0b013e3181903da7","article-title":"Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.","volume":"86","author":"Tan","year":"2008","journal-title":"Transplantation"},{"key":"R14-10-20210211","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.transproceed.2008.06.037","article-title":"Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.","volume":"40","author":"Villanueva","year":"2008","journal-title":"Transplant Proc"},{"key":"R15-10-20210211","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.tp.0000225760.09969.1f","article-title":"Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.","volume":"82","author":"Bunnapradist","year":"2006","journal-title":"Transplantation"},{"issue":"2 suppl","key":"R16-10-20210211","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1097\/01.tp.0000187035.22298.ba","article-title":"Review of major clinical trials with mycophenolate mofetil in renal transplantation.","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0b013e3181b724a5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:00:42Z","timestamp":1786039242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200910150-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,15]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181b724a5","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,15]]}}}